rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLCrsp-3368Research ArticleСтатьиArticlesРезолюция совета экспертов «Современные стратегии терапии системной красной волчанки»РедакционнаяСтатья202329062023613389391Copyright © Редакционная С., 20232023Редакционная С.Редакционная С.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3368
.
ReferencesKaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39Parra Sánchez AR, Voskuyl AE, van Vollenhoven RF. Treat-totarget in systemic lupus erythematosus: Advancing towards its implementation. Nat Rev Rheumatol. 2022;18(3):146-157. doi: 10.1038/s41584-021-00739-3Parra Sánchez AR, Voskuyl AE, van Vollenhoven RF. Treat-totarget in systemic lupus erythematosus: Advancing towards its implementation. Nat Rev Rheumatol. 2022;18(3):146-157. doi: 10.1038/s41584-021-00739-3Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: New drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020;59(Suppl 5):v69-v81. doi: 10.1093/rheumatology/keaa403Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: New drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020;59(Suppl 5):v69-v81. doi: 10.1093/rheumatology/keaa403Соловьев СК, Асеева ЕА, Попкова ТВ, Лила АМ, Мазуров ВИ, Насонов ЕЛ. Системная красная волчанка: новые горизонты диагностики и терапии. Научно-практическая ревматология. 2020;58(1):5-14. doi: 10.14412/1995-4484-2020-5-14Solovyev SK, Aseeva EA, Popkova TV, Lila AM, Mazurov VI, Nasonov EL. Systemic lupus erythematosus: New horizons for diagnosis and therapy. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(1):5-14 (In Russ.). doi: 10.14412/1995-4484-2020-5-14Насонов ЕЛ, Соловьев СК, Аршинов АВ. Системная красная волчанка: история и современность. Научно-практическая ревматология. 2022;60(4):397-412. doi: 10.47360/1995-4484-2022-397-412Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: History and modernity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):397-412 (In Russ.). doi: 10.47360/1995-4484-2022-397-412Porta S, Danza A, Arias Saavedra M, Carlomagno A, Goizueta MC, Vivero F, et al. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. J Clin Med. 2020;9(9): 2709. doi: 10.3390/jcm9092709Porta S, Danza A, Arias Saavedra M, Carlomagno A, Goizueta MC, Vivero F, et al. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. J Clin Med. 2020;9(9): 2709. doi: 10.3390/jcm9092709Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452-461. doi: 10.14412/1995-4484-2019-452-461Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type I interferon: New evidence. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(4):452-461 (In Russ.). doi: 10.14412/1995-4484-2019-452-461Bruera S, Chavula T, Madan R, Agarwal SK. Targeting type I interferons in systemic lupus erythematous. Front Pharmacol. 2023;13:1046687. doi: 10.3389/fphar.2022.1046687Bruera S, Chavula T, Madan R, Agarwal SK. Targeting type I interferons in systemic lupus erythematous. Front Pharmacol. 2023;13:1046687. doi: 10.3389/fphar.2022.1046687Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol. 2022;18(10):575-590. doi: 10.1038/s41584-022-00826-zPsarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol. 2022;18(10):575-590. doi: 10.1038/s41584-022-00826-zGoulden B, Isenberg D. Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus. Expert Opin Biol Ther. 2021;21(4):519-528. doi: 10.1080/14712598.2021.1841164Goulden B, Isenberg D. Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus. Expert Opin Biol Ther. 2021;21(4):519-528. doi: 10.1080/14712598.2021.1841164Riggs JM, Hanna RN, Rajan B, Zerrouki K, Karnell JL, Sagar D, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000261. doi: 10.1136/lupus-2018-000261Riggs JM, Hanna RN, Rajan B, Zerrouki K, Karnell JL, Sagar D, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000261. doi: 10.1136/lupus-2018-000261Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al.; CD1013 Study Investigators. Anifrolumab, an antiinterferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376-386. doi: 10.1002/art.39962Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al.; CD1013 Study Investigators. Anifrolumab, an antiinterferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376-386. doi: 10.1002/art.39962Chatham WW, Furie R, Saxena A, Brohawn P, Schwetje E, Abreu G, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: Results of a phase II open-label extension study. Arthritis Rheumatol. 2021;73(5):816-825. doi: 10.1002/art.41598Chatham WW, Furie R, Saxena A, Brohawn P, Schwetje E, Abreu G, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: Results of a phase II open-label extension study. Arthritis Rheumatol. 2021;73(5):816-825. doi: 10.1002/art.41598Furie R, Morand EF, Bruce IN, Manzi S, Kalunian K, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208-e219. doi: 10.1016/S2665-9913(19)30076-1Furie R, Morand EF, Bruce IN, Manzi S, Kalunian K, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208-e219. doi: 10.1016/S2665-9913(19)30076-1Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221. doi: 10.1056/NEJMoa1912196Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221. doi: 10.1056/NEJMoa1912196Jayne D, Rovin BH, Mysler E, Furie R, Houssiau F, Trasieva T, et al. POS0690. Randomized, controlled, phase 2 trial of type 1 IFN inhibitor anifrolumab in patients with active proliferative lupus nephritis. Ann Rheum Dis. 2021;80:592.Jayne D, Rovin BH, Mysler E, Furie R, Houssiau F, Trasieva T, et al. POS0690. Randomized, controlled, phase 2 trial of type 1 IFN inhibitor anifrolumab in patients with active proliferative lupus nephritis. Ann Rheum Dis. 2021;80:592.Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: An overview from clinical trials. Mod Rheumatol. 2021;31(1):1-12. doi: 10.1080/14397595.2020.1812201Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: An overview from clinical trials. Mod Rheumatol. 2021;31(1):1-12. doi: 10.1080/14397595.2020.1812201Kirou KA, Dall Era M, Aranow C, Anders HJ. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol. 2022;13:980079. doi: 10.3389/fimmu.2022.980079Kirou KA, Dall Era M, Aranow C, Anders HJ. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol. 2022;13:980079. doi: 10.3389/fimmu.2022.980079Loncharich MF, Anderson CW. Interferon inhibition for lupus with anifrolumab: Critical appraisal of the evidence leading to FDA approval. ACR Open Rheumatol. 2022;4(6):486-491. doi: 10.1002/acr2.11414Loncharich MF, Anderson CW. Interferon inhibition for lupus with anifrolumab: Critical appraisal of the evidence leading to FDA approval. ACR Open Rheumatol. 2022;4(6):486-491. doi: 10.1002/acr2.11414Bruce IN, Golam S, Steenkamp J, Wang P, Worthington E, Desta B, et al. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J Comp Eff Res. 2022;11(10):765-777. doi: 10.2217/cer2022-0040Bruce IN, Golam S, Steenkamp J, Wang P, Worthington E, Desta B, et al. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J Comp Eff Res. 2022;11(10):765-777. doi: 10.2217/cer2022-0040Liu Z, Cheng R, Liu Y. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review. Front Immunol. 2022;13:996662. doi: 10.3389/fimmu.2022.996662Liu Z, Cheng R, Liu Y. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review. Front Immunol. 2022;13:996662. doi: 10.3389/fimmu.2022.996662Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: Pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-1675. doi: 10.1093/rheumatology/kew431Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: Pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-1675. doi: 10.1093/rheumatology/kew431
The authors declare that there are no conflicts of interest present.